Shares of Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) have been assigned an average rating of “Buy” from the ten analysts that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $19.48.
Several research firms recently commented on BLCM. BidaskClub raised Bellicum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Thursday, January 4th. ValuEngine raised Bellicum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Wednesday, January 3rd. Zacks Investment Research cut Bellicum Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, January 12th. Cantor Fitzgerald reissued an “overweight” rating and set a $10.00 target price (down from $12.00) on shares of Bellicum Pharmaceuticals in a research note on Wednesday, January 31st. Finally, Wells Fargo cut Bellicum Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $6.00 target price for the company. in a research note on Wednesday, January 31st.
BLCM opened at $7.52 on Friday. Bellicum Pharmaceuticals has a 12 month low of $5.02 and a 12 month high of $14.49. The firm has a market cap of $252.46, a P/E ratio of -2.65 and a beta of 0.47. The company has a quick ratio of 8.37, a current ratio of 8.37 and a debt-to-equity ratio of 0.41.
Bellicum Pharmaceuticals (NASDAQ:BLCM) last released its earnings results on Tuesday, March 13th. The biopharmaceutical company reported ($0.61) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.69) by $0.08. The company had revenue of ($0.07) million for the quarter, compared to analyst estimates of $0.08 million. research analysts forecast that Bellicum Pharmaceuticals will post -2.67 EPS for the current fiscal year.
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Prosight Management LP purchased a new stake in Bellicum Pharmaceuticals during the 4th quarter worth about $2,534,000. Vident Investment Advisory LLC lifted its holdings in Bellicum Pharmaceuticals by 37.2% during the 4th quarter. Vident Investment Advisory LLC now owns 150,426 shares of the biopharmaceutical company’s stock worth $1,265,000 after buying an additional 40,780 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in Bellicum Pharmaceuticals by 14.9% during the 4th quarter. Goldman Sachs Group Inc. now owns 148,860 shares of the biopharmaceutical company’s stock worth $1,252,000 after buying an additional 19,257 shares during the last quarter. Schwab Charles Investment Management Inc. lifted its holdings in Bellicum Pharmaceuticals by 47.1% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 131,217 shares of the biopharmaceutical company’s stock worth $1,516,000 after buying an additional 41,995 shares during the last quarter. Finally, Millennium Management LLC purchased a new stake in Bellicum Pharmaceuticals during the 4th quarter worth about $1,045,000. 54.58% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY WARNING: This news story was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2018/04/22/bellicum-pharmaceuticals-inc-blcm-given-consensus-rating-of-buy-by-brokerages.html.
About Bellicum Pharmaceuticals
Bellicum Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The company's clinical product candidates include BPX-501, an adjunct T cell therapy in multiple Phase I/II clinical trials, administered after allogeneic hematopoietic stem cell transplantation; and BPX-601, a GoCAR-T product candidate in Phase I clinical trial for treating solid tumors expressing the prostate stem cell antigen.
Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.